$DMRA News

Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value

Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target

Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60

Damora Therapeutics: Potential Payday Is A Long Way Off

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside

Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Study Of DMR-001 To Treat Patients With Mutcalr-Driven Essential Thrombocythemia And Myelofibrosis

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

HC Wainwright & Co. Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target

Damora Announces Redomestication from Delaware to Cayman Islands

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)